Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02238756 | Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy Adults | PHASE1 | COMPLETED | 72 | — | — | Sep 1, 2014 | Nov 1, 2016 | Jun 6, 2018 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| CV8102 | EXPERIMENTAL | - |
| Rabipur | ACTIVE_COMPARATOR | - |
| CV8102 + Rabipur | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| CV8102 | BIOLOGICAL | Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart |
| Rabipur | BIOLOGICAL | Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart |
| CV8102 + Rabipur | BIOLOGICAL | Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart |
Inclusion Criteria: 1. Compliant with protocol procedures and available for clinical F/U until the protocol-defined end of the trial 2. Physical examination and laboratory results without clinically significant findings 3. Body Mass Index (BMI) ≥ 18.0 and ≤ 32.0 kg/m2 4. Subjects must use reliable ...